Heron Therapeutics, Inc. (HRTX), Tuesday said that it has entered into a settlement agreement to resolve the patent litigations with Mylan Pharmaceuticals, Inc., a Viatris Inc. company, related to CINVANTI and APONVIE.
As per the agreement, Heron has granted Mylan a license to market generic versions of CINVANTI and APONVIE in the United States beginning June 1, 2032, or earlier under certain customary circumstances.
These patent litigations were initiated by Heron in September 2023 and January 2024 when Mylan submitted abbreviated new drug applications seeking FDA approval of generic versions of CINVANTI and APONVIE, respectively, prior to the expiration of the Heron Patents in 2035.
Heron's CINVANTI, same formulation as and APONVIE, is approved for the prevention of chemotherapy-induced nausea and vomiting.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.